| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1802 | 2015 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1279 | 2016 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1259 | 2011 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 701* | 2019 |
| Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study IW Flinn, R Van Der Jagt, BS Kahl, P Wood, TE Hawkins, D MacDonald, ... Blood, The Journal of the American Society of Hematology 123 (19), 2944-2952, 2014 | 695 | 2014 |
| International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease DC Fajgenbaum, TS Uldrick, A Bagg, D Frank, D Wu, G Srkalovic, ... Blood, The Journal of the American Society of Hematology 129 (12), 1646-1657, 2017 | 553 | 2017 |
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798, 2020 | 527 | 2020 |
| Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial F Van Rhee, RS Wong, N Munshi, JF Rossi, XY Ke, A Fosså, D Simpson, ... The lancet oncology 15 (9), 966-974, 2014 | 474 | 2014 |
| Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine … Stem Cell Trialists’ Collaborative Group Journal of clinical oncology: official journal of the American Society of …, 2005 | 462 | 2005 |
| A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies S Couban, DR Simpson, MJ Barnett, C Bredeson, L Hubesch, ... Blood, The Journal of the American Society of Hematology 100 (5), 1525-1531, 2002 | 389 | 2002 |
| Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL CS Tam, J Trotman, S Opat, JA Burger, G Cull, D Gottlieb, R Harrup, ... Blood, The Journal of the American Society of Hematology 134 (11), 851-859, 2019 | 367 | 2019 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease F Van Rhee, P Voorhees, A Dispenzieri, A Fosså, G Srkalovic, M Ide, ... Blood, The Journal of the American Society of Hematology 132 (20), 2115-2124, 2018 | 360 | 2018 |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial JH Lipton, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, ... The Lancet Oncology 17 (5), 612-621, 2016 | 280 | 2016 |
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3 … AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ... The Lancet Oncology 18 (3), 297-311, 2017 | 273 | 2017 |
| First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5 … IW Flinn, R Van Der Jagt, B Kahl, P Wood, T Hawkins, D MacDonald, ... Journal of Clinical Oncology, 2019 | 263 | 2019 |
| Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study E Bachy, JF Seymour, P Feugier, F Offner, A López-Guillermo, D Belada, ... Journal of Clinical Oncology 37 (31), 2815-2824, 2019 | 248 | 2019 |
| Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ... The Lancet Haematology 6 (9), e459-e469, 2019 | 242 | 2019 |
| Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ... The Lancet Haematology 6 (9), e448-e458, 2019 | 224 | 2019 |
| Oncogenic KRAS regulates amino acid homeostasis and asparagine biosynthesis via ATF4 and alters sensitivity to L-asparaginase DM Gwinn, AG Lee, M Briones-Martin-del-Campo, CS Conn, DR Simpson, ... Cancer cell 33 (1), 91-107. e6, 2018 | 216 | 2018 |
| Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients … J Hiemenz, P Cagnoni, D Simpson, S Devine, N Chao, J Keirns, W Lau, ... Antimicrobial agents and chemotherapy 49 (4), 1331-1336, 2005 | 185 | 2005 |
